Biostock interview: Chordate CEO Anders Weilandt on the Q1 report

After Chordate released its interim report for Q1 2024, Biostock interviewed the company’s CEO, Anders Weilandt. In the interview, he talks about the company’s position today compared to a year ago.

“We have made progress since we started building proof-of-concept in the market after the summer. It is a long-term effort that takes time – but we are building step by step. Revenues from repetitive sales are starting to show, albeit at low levels.”

Read the full interview

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy